Bibliothek

X
feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Digitale Medien
    Digitale Medien
    Correlation between serum antibody-levels against group B streptococci and gestational age in newborns (1984)
    Springer
    European journal of pediatrics 142 (1984), S. 86-88 
    Details
    ISSN: 1432-1076
    Schlagwort(e): Group B streptococci: types Ia, Ib, II, III ; IgG antibody levels ; Premature infants ; Early onset septicemia
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Sera from 33 newborn infants with gestational ages ranging from 27 to 41 weeks were tested by radioimmunoassay for IgG antibodies to surface antigens of group B streptococci (GBS) types Ia, Ib, II and III. Antibody levels to GBS antigens were positively correlated to gestational age and birthweight. However, only the correlations for anti-Ia and anti-II antibody levels reached statistical significance. Mean antibody concentrations in infants below 34 weeks of gestation were significantly lower for type Ia (P〈0.001), type II (P〈0.001) and type III (P=0.05) than in infants above this limit. These findings might explain the higher rate of serious GBS-infections found among prematures as compared to full-term infants.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/BF00445584
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
  • 2
    Digitale Medien
    Digitale Medien
    Long-Term Responses to Treatment Including Ritonavir or Nelfinavir in HIV-1-Infected Children (2000)
    Springer
    Infection 28 (2000), S. 287-296 
    Details
    ISSN: 1439-0973
    Schlagwort(e): Key Words Ritonavir ; Nelfinavir ; Children ; Antiretroviral agents ; HIV-1
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Summary Background: Knowledge concerning the long-term antiretriviral and immunological efficacy of protease inhibitors in children is limited. Patients and Methods: An open-label, prospective, multicenter clinical trial was conducted over a period of 72 weeks in Switzerland. 60 HIV-1 infected children (aged 0.3–16.9 years) naive to protease inhibitors were enrolled. Ritonavir or nelfinavir and at least one new nucleoside reverse transcriptase inhibitor were introduced into the durrent treatment regimen. HIV-1 RNA levels and CD4 cell counts were monitored after introducing the protease inhibitor, and the tolerability and safety of the drugs were assessed. Results: Dictated by chronological availability, 37 children received ritonavir and 23 nelfinavir. At baseline, children given ritonavir had higher mean plasma HIV-1 RNA levels (5.03 vs 4.63 log10 copies/ml; p = 0.001) and lower mean CD4 cell counts (277 vs 555 cells/μl; p = 0.009) than children given nelfinavir. Antiretroviral treatment (ART) naive children showed higher mean plasma HIV-1 RNA levels than non-naive (5.18 vs 4.64 log10 copies/ml; p = 0.02). The decline in plasma HIV-1 RNA levels 72 weeks after treatment with ritonavir and nelfinavir was −2.17 and −1.30 log10 copies/ml, respectively (p = 0.006) and in ART-naive vs non-naive patietns −2.70 vs − 1.39 log10 copies/ml (p ≤ 0.01). 69% of ART-naive patients and 32% of non-naive patients achieved sustained plasma HIV-1 RNA levels 〈 400 copies/ml. Increases in CD4 cells were higher in ART naive compared to non-naive patients (p 〈 0.04). Conclusion: The antiretroviral and immunologic benefits of protease inhibitors are more profound in ART-naive than in non-naive children.
    Materialart: Digitale Medien
    URL: http://dx.doi.org/10.1007/s150100070021
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Artikel (Nationallizenzen)
    Volltext
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...